Hemodynamic support in high-risk percutaneous coronary interventions and cardiogenic shock

Over the last 50 years there have been rapid advances in the development of ventricular assist devices in the cardiac catheterization laboratory. An ideal device is one that is easy to insert, simple to use, provides effective support, is associated with minimal complications and provides a morbidity and mortality benefit for the patient. In this article we will review the currently available percutaneous left ventricular assist devices and the evidence to support their use.

Keywords: cardiogenic shock n high-risk percutaneous coronary intervention n Impella® n intra-aortic balloon pump n percutaneous left ventricular assist devices n TandemHeart®

Claudia A Martinez, Apurva O Badheka & William W O’Neill*
University of Miami, Miller School of Medicine, Miami, FL, USA
*Author for correspondence: woneill@med.miami.edu

Temporary percutaneous left ventricular (LV) assist devices (TPLVAD) have been approved for hemodynamic support in the setting of cardiogenic shock (CS) or for high-risk percutaneous coronary interventions (PCI). An ‘ideal’ TPLVAD is a device that can be rapidly inserted, provides adequate support, is simple to use, has few vascular complications and is easy to remove. TPLVADs can provide valuable time and help stabilize a ‘crashing and burning’ patient until recovery or prior to undertaking further definitive treatment measures.

CS is a state of end-organ hypoperfusion due to cardiac dysfunction. Suggestive hemodynamic parameters include persistent hypotension (systolic blood pressure <80–90 mmHg or mean arterial pressure 30 mmHg lower than baseline) with severe reduction in the cardiac index (CI; <1.8 l/min per m² without support or <2.0–2.2 l/min per m² with support) and adequate or elevated filling pressures [1]. Although a slight temporal decline in rates of CS has been observed with the introduction of routine PCI, CS still complicates approximately 5–8% of ST-elevation myocardial infarction (STEMI) and 2.5% of non-STEMI cases [2]. Patients developing CS have a very high mortality rate (>50%) during the index hospitalization [3]. TPLVAD have been used in the setting of CS to provide temporizing measures.

High-risk PCI does not have a universal definition. Nevertheless, most studies consider high-risk PCI to be interventions in patients with moderately depressed cardiac function, or in the setting of hemodynamic instability or due to the complex nature of the intervention (coronary or structural) [4,5]. In such settings, even brief episodes of myocardial ischemia or hypotension can set off a life threatening downward spiral of decreased cardiac output, coronary hypoperfusion, heart failure and hemodynamic collapse. Prophylactic use of hemodynamic support devices is therefore also employed in such cases, to prevent adverse outcomes [6,10].

Background

Hemodynamic support using extracorporeal membrane oxygenators has been described since the early 1950s [7]. Subsequently, the intra-aortic balloon pump (IABP) was introduced in the early 1960s and has been used increasingly since then (Figure 1). This was followed by the introduction of cardiopulmonary support systems in the 1970s, which used large femoral cannulas to pump femoral venous blood through an oxygenator and then back into the femoral artery. The high percentage of multiorgan complications, however, limited their widespread use. The Hemopump® (Medtronic, Inc., MN, USA) introduced in the 1980s was the first active forward-flow intraventricular pump; however, it failed to be readily adopted. The interim period was marked by widespread reliance on IABP, which became the workhorse of cardiac support along with extracorporeal membrane oxygenation (ECMO). Nevertheless, ECMO consists of combined cardiac and respiratory support and is more technically demanding. ECMO has been associated with a 40% survival benefit when used during CS as a bridge to transplant or destination therapy [8–11]. The details of ECMO as a cardiopulmonary adjunct are outside the scope of this article.
In the early 2000s, the TandemHeart® (Cardiac Assist, Inc., PA, USA) received US approval and has since been extensively used in the cardiac catheterization laboratory in the hands of experienced operators. More recently the Impella® device (Abiomed, Inc., MA, USA) has been introduced into the market and has gained rapid acceptance due to its ease of use (Figure 2). The Reitan catheter pump (CardioBridge GmbH, Hechingen, Germany) is an experimental intra-aortic axial pump that can provide flow rates of up to 20 l/min but is not yet commercially available in the USA [102].

At present, there are three TPLVAD commercially available in the USA that are frequently used in the catheterization laboratory – the IABP, TandemHeart and the Impella Recover LP 2.5 (Figures 3 & 4). Each has its own set of advantages and challenges (Tables 1 & 2 & box 1). In this review, we will attempt to summarize these devices and the literature supporting their use. Impella 5 is a larger version of the Impella 2.5 and provides up to 5 l of cardiac output. Since it requires a subclavian cutdown and is mostly implanted by surgeons, its utility in the catheterization laboratory is limited.

Review of evidence supporting TPLVAD use in CS

IABP

The current American College of Cardiology (ACC)/American Heart Association (AHA) guidelines on STEMI list IABP therapy as a Class IB recommendation in the setting of CS [12]. IABP therapy also received a Class IIA recommendation in the ACC/AHA guidelines for patients with non-STEMI and refractory ischemia [13]. The IABP is the most widely used support device in the USA in patients with acute myocardial infarction (MI). In the Benchmark registry involving over 22,000 patients, IABP use was successful in >97% of patients, with major complications arising in <3% of the cases [14].

Various studies, including randomized trials, have investigated IABP use in MI and CS [15–21]. Recent meta-analyses have confirmed the benefits of IABP in patients treated with thrombolysis. However, IABP therapy in adjunct to primary PCI did not demonstrate any benefits regarding 30-day mortality or changes in LV ejection fraction (EF; Figure 5 & 6) [22]. In addition, IABP use was associated with a significant 6% increase in 30-day mortality in patients treated with PCI with a nonsignificant increase in stroke and bleeding rates. It is worth noting that of the three randomized, controlled trials included in this metaanalysis comparing IABP to no-IABP therapy during primary PCI for STEMI, two of them (Ohman et al. and Stone et al.) excluded patients with CS [17,18]. The third study by Van’t Hof et al. included patients with CS. However, patients with STEMI and signs of CS who were assigned to standard treatment, crossover to IABP was prespecified by Van’t Hof [19]. In essence, all patients with CS were switched to IABP support. An ‘on treatment analysis’ was not mentioned and only results from ‘per protocol analysis’ were shown. This highlights the challenges of carrying out a randomized trial evaluating TPLVAD support in STEMI patients with CS. In conclusion, despite the results depicted in this metaanalysis, there is still not enough evidence to qualify or disqualify the beneficial effects of IABP during CS.
TandemHeart

In a small randomized trial of patients with STEMI and CS, Thiele et al. showed up to 4 l of assisted cardiac support and improvement in CI and LV filling pressures with the use of TandemHeart [23]. Subsequent reports showed superior hemodynamic support when using TandemHeart versus IABP without an observable impact on 30-day mortality (Figure 7) [23,24]. Unfortunately, these hemodynamic benefits were accompanied by an increase in vascular complications, including access site bleeding and limb ischemia due to the large size cannulas. Appropriate selection of patients with vascular access to accommodate this device is necessary to prevent vascular complications. Despite the hemodynamic benefits observed with TandemHeart, the clinical data available to support its use in CS remains limited.

Impella

The ISAR-SHOCK study randomized 26 patients with STEMI and CS to Impella 2.5 or IABP (Figures 8 & 9) [25]. The CI increased by 0.49 ± 0.46 l/min in the Impella group compared with 0.11 ± 0.31 l/min in the IABP group at 30 min (p = 0.02). However, there was no difference in 30-day mortality (46% in both groups). Lam et al. also showed improved microvascular indices in anterior STEMI.
Table 1. Characteristics of percutaneous left ventricular support devices.

<table>
<thead>
<tr>
<th></th>
<th>IABP</th>
<th>TandemHeart®</th>
<th>Impella® 2.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Description</td>
<td>Over the wire flexible catheter positioned in descending aorta through femoral artery access</td>
<td>Removes oxygenated blood through a trans-septal left atrial cannula and delivers it to the aorta via a transfemoral cannula, driven by an external microprocessor controller. Provides up to 5 l/min of blood flow. Power is supplied by a direct current, electromagnetic motor that operates at 3000–75,000 rpm. In experienced centers, insertion and assembly can take 30 min [36,38,43]. Has been used in some patients for up to 14 days.</td>
<td>Catheter-based impeller driven axial flow pump that is inserted retrograde across the aortic valve via the femoral artery. Provides up to 2.5 l/min of cardiac output. Driven by an electrical motor connected to the inflow cannula. Connected to a mobile console that manages the rotational speed and displays the pressure. Median insertion time is &lt;30 min. Approved in Europe for use up to 5 days.</td>
</tr>
<tr>
<td>Mechanism</td>
<td>Inflation/deflation of balloon increases arterial, diastolic pressure and coronary perfusion and perfusion to other organ systems. Decreases heart rate, LV end diastolic pressure, left atrial pressure and oxygen consumption (Figure 10)</td>
<td>Active unloading of the left atrium and bypassing the left ventricle by diverting blood to femoral artery when used as a LVAD. When used for right ventricular support, active unloading of the right atrium and bypassing the right ventricle by diverting blood to the pulmonary artery</td>
<td>Pumps blood from the LV into the ascending aorta. Provides active unloading of the LV and subsequently decreased left atrial pressure</td>
</tr>
<tr>
<td>Sheath Size</td>
<td>8-Fr sheath, 7.5 Fr when used sheathless</td>
<td>21-Fr venous transeptal inflow cannula with large end holes at the distal tip and 14 side holes to aspirate oxygenated blood from the left atrium. Femoral artery sheath 15–17-Fr cannula or two 12-Fr arterial cannulas for both femoral arteries</td>
<td>12-Fr pump head and 9-Fr catheter that requires a 13-Fr insertion sheath</td>
</tr>
<tr>
<td>Indications</td>
<td>CS, high-risk PCI, structural procedures</td>
<td>CS, high-risk PCI, structural procedures</td>
<td>CS, high-risk PCI, structural procedures</td>
</tr>
<tr>
<td>Contraindications</td>
<td>Peripheral vascular disease, aortic regurgitation and coagulopathy due to liver or renal dysfunction</td>
<td>Peripheral vascular disease, previous VSD (hypoxemia due to right-to-left shunt). In the setting of mechanical resuscitation is technically challenging. Severe right heart failure. Coagulopathy due to liver or renal dysfunction</td>
<td>Peripheral vascular disease, mural thrombus in the LV. The presence of a mechanical aortic valve. Aortic valve disease (relative contraindication). Extreme aorta tortuosity or calcification. Coagulopathy due to liver or renal dysfunction, recent neurological event or HOCM. Aneurysm or necrotomy or severe anomaly of the ascending aorta and/or the aortic arch. VSD after MI. Anatomic conditions precluding insertion of the pump. Other illnesses or therapy requirements precluding use of the pump</td>
</tr>
<tr>
<td>Pros</td>
<td>Easy to use, rapid insertion inside or outside of the catheterization laboratory. Decreases afterload, increases coronary perfusion by augmenting diastolic pressure and mean arterial pressure. Support of choice in the setting of VSDs</td>
<td>Diverts oxygenated blood from the left atrium into the systemic circulation. Increases cardiac output and blood pressure. Decreases afterload and preload. Increases tissue perfusion. Reversal of metabolic acidosis. Restores microvascular blood flow. Reduction in infarct size. Rapid hemodynamic support despite native heart rhythm. Unloads the left ventricle</td>
<td>Simple to use, unloads the LV and delivers blood to the ascending aorta. Reduces oxygen consumption and infarct size. Increase cardiac output. Reduction of LV end-diastolic pressure and volume. Maintaining forward flow, LV unloading and coronary flow independently of intrinsic cardiac function</td>
</tr>
<tr>
<td>Cons</td>
<td>Not an active pump, requires intrinsic LV function. Depends on balloon position and ECG</td>
<td>Bigger vascular profile and higher risk of vascular complications. Complications related to trans-septal puncture</td>
<td>Bigger vascular profile than IABP and increased risk of vascular complications. Theoretical concern of aortic valve damage</td>
</tr>
</tbody>
</table>

CS: Cardiogenic shock; ECG: Electrocardiogram; HOCM: Hypertrophic obstructive cardiomyopathy; IABP: Intra-aortic balloon pump; LV: Left ventricle; LVAD: Left ventricular assist device; MI: Myocardial infarction; PCI: Percutaneous coronary intervention; VSD: Ventricular septal defect.
patients treated with Impella 2.5 as compared with controls using sublingual side stream dark field microscopy [26].

Safety and feasibility in patients undergoing PCI with anterior STEMI was assessed in the nonrandomized AMC-MACH study, which showed a greater decrease in pulmonary capillary wedge pressure and improvement in LV function in patients who received Impella support compared with the IABP controls [27]. Longer follow-up from the study showed that three-day support with the Impella LP 2.5 was not associated with adverse effects on the aortic valve and lead to significantly improved recovery in the EF [28].

In the acute MI cohort of the USPella registry, the Impella device was used mostly after conventional therapies had failed. It improved the CI from 1.9 to 2.5 l/min/m², increased mean arterial pressure from 62 to 87 mmHg, decreased wedge pressure from 28 to 20 mmHg, decreased overall systemic vascular resistance and improved EF from 29 to 37%. Of the patients with acute MI and CS, a total of 58% were discharged compared with 89% of MI patients without CS [103].

More recently, the Academic Medical Center researchers have shown that in patients with STEMI and profound CS, survival was improved in patients who received immediate Impella 5.0 treatment, as well as in patients who were upgraded from 2.5 to 5.0 support, compared with patients who received only Impella 2.5 [29]. No randomized controlled trial has demonstrated superiority between IABP and Impella for long-term outcomes. The ongoing IMPRESS in STEMI trial is presently investigating the use of Impella versus IABP support in large anterior STEMI being treated with PCI [104].

### Table 2. Overview of complication risks by device profile.

<table>
<thead>
<tr>
<th>Complications</th>
<th>IABP</th>
<th>TandemHeart®</th>
<th>Impella®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vascular</td>
<td>+</td>
<td>+++</td>
<td>++</td>
</tr>
<tr>
<td>Nonvascular</td>
<td>+</td>
<td>+++</td>
<td>++</td>
</tr>
</tbody>
</table>

*: risk of developing complications; IABP: Intra-aortic balloon pump.

Box 1. Complications related to the use of percutaneous hemodynamic support devices.

**Vascular**
- Limb ischemia
- Laceration
- Major hemorrhage
- Cholesterol embolization
- Compartment syndrome
- Retroperitoneal hematoma
- Arterial or venous thrombosis
- Aortic dissection

**Nonvascular**
- Cerebrovascular accidents
- Sepsis
- Balloon rupture
- Thrombocytopenia
- Hemolysis
- Peripheral neuropathy
- Thromboembolism
- Hypothermia
- Damage of aortic valve
- Potential complications from transeptal puncture
- Puncture of the aorta, posterior free wall of the right atrium, coronary sinus
- Dislodgement of the arterial cannula
- Residual left to right shunt

†Applies only to intra-aortic balloon pump.
‡Applies only to Impella®.
§Applies only to TandemHeart®.

Review of evidence supporting TPLVAD use in high-risk PCI

**IABP**

The IABP is the most widely used support device for high-risk PCI in the USA [30].

Figure 5. Forest plot depicting outcomes including (A) the risk differences in 30-day mortality, (B) the mean differences in left ventricular ejection fraction, and the risk differences in (C) stroke and (D) major bleeding rate.

IABP: Intra-aortic balloon counterpulsation; LVEF: Left ventricular ejection fraction; PCI: Percutaneous coronary intervention. Reproduced with permission from [22].
Recently, the BCIS investigators randomized patients with low EF and severe multivessel disease to control versus prophylactic IABP strategy. In this trial, prophylactic IABP use did not reduce major adverse cardiac and cerebrovascular event (MACCE) or improve all cause mortality [31]. However, a trend in the reduction of mortality at 6 months was observed for the IABP arm. Another interesting observation was that operators were unsure whether support was required and in which patient, since half the patients received no support. Importantly, one-fifth of the patients in the ‘watchful waiting’ arm had to ‘crash’ to end up on IABP support. These patients had a worse outcome overall. Unfortunately, no predictive features for which patients are likely to ‘crash’ exists.

The results of the BCIS trial contradict prior nonrandomized or retrospective data demonstrating decreased MACCE in an elective...
versus provisional or rescue IABP strategy [32–34]. In summary, the BCIS trial demonstrated that when using prophylactic versus no planned IABP, there was no significant difference in terms of cardiovascular complication and 6-month mortality. There was a statistically significant difference in terms of major procedural complication in favor of the elective group, despite a trend towards a higher rate of bleeding and vascular complications in the elective group.

The recent CRISP-AMI trial addressed the use of IABP in patients with anterior wall STEMI without CS who were undergoing PCI [35]. Again there was no reduction in infarct size (as assessed by cardiac MRI) or improvement in clinical outcomes at 6 months.

**TandemHeart**

Vranckx *et al.* have demonstrated the efficacy of the TandemHeart for providing stable total LV support in the setting of high-risk PCI. In 23 patients followed over a 6-year period, TandemHeart insertion required an average of 35 min for implantation and resulted in significant reductions in LV filling pressures, pulmonary capillary wedge pressures and an increase in arterial pressure. However, the mortality of the cohort was modestly high at 22%, with vascular and bleeding complications in almost one-third of the patients [36]. Although the TandemHeart and Impella devices have not been compared head to head, Froesch *et al.* recently provided some insight into this [37]. In a single-center retrospective experience (*n* = 75) more TPLVADs were used in the setting of CS (*n* = 26). TandemHeart was also more likely to be used for CS. The Impella was more likely to be used for high-risk PCI. Mortality at 6 months was 23% after PCI and 55% after CS. Complication rates were also as high as one in three [2]. In a subsequent study, Vranckx *et al.* demonstrated a reduced procedural risk and excellent periprocedural circulatory support using TandemHeart in nine patients for left main PCI, who were otherwise declined for CABG [38]. Postprocedure vascular issues were observed in four of these patients. There have also been other smaller reports demonstrating similar procedural success at the expense of an increased rate of vascular complications [39–42]. Nevertheless, the more recent use of suture-mediated femoral artery preclosure may prevent vascular complications when used in conjunction with IABP devices [43].

**Impella**

The PROTECT I study was a prospective feasibility trial that investigated 20 patients with EF of <35% who underwent high-risk PCI of either unprotected left main artery or of the last patent coronary conduit with concomitant Impella support [6]. The device provided hemodynamic support and was safe to use. Similar results were also available in smaller studies in Europe [44]. The multicenter Europella registry involving 144 consecutive patients showed that high-risk PCI with Impella support was associated with low (5.5%) mortality with no MIs [45]. Major bleeding was 6%
and vascular complications were 4%. These results were also reproduced on the other side of the Atlantic in the high-risk PCI subgroup of the USPella registry. Reported overall rate of MACCE was low at 6% and 30-day survival rate was 97% \[103\]. Real world experiences using Impella for high-risk PCI have also been very promising \[46\].

Remmelink et al. shed further light on the hemodynamic support provided by Impella during high-risk PCI. Intracoronary measurements were performed in a nonstenotic coronary artery after PCI using adenosine-induced hyperemia at different Impella support levels. LV unloading by Impella led to increased aortic and intracoronary pressure, hyperemic flow velocity and coronary flow velocity reserve and decreased microvascular resistance. The increased coronary flow by Impella support is due to both increased perfusion pressure and decreased intramyocardial resistance from reduced LV stretch \[47\]. The same investigators, using a pressure conductance catheter, also demonstrated dose dependant decrease in end-diastolic wall stress and improved diastolic compliance by Impella LV unloading \[48\].

These encouraging results led to the PROTECT II trial, which randomized patients with high-risk PCI to IABP versus Impella 2.5. After an interim analysis the trial was stopped midway due to futility \[49\]. However, the final results from 447 patients showed a 21% reduction in major adverse events with Impella, compared with the IABP group (40.8 vs 51.4%; \( p = 0.029 \)). This was driven mainly by a decrease in repeat revascularization. The Impella device provided better stability and support during PCI allowing the operator to perform longer and more complex procedures, with more aggressive use of atherectomy \[105\]. An even greater benefit was observed in the prespecified subgroup of high-risk PCI without atherectomy subgroup (88% of study), with the Impella device providing a 29% reduction of major adverse events over IABP. Hospital charges for all PROTECT II patients at 90 days were on average US$19,000 lower with Impella than with IABP use, providing a further economic stimulus \[105\]. The use of Impella in the setting of aortic stenosis and high-risk PCI has also recently been reported, especially in the setting of concomitant valvuloplasty \[5,50\].

**Conclusion**

Technical advances in coronary intervention devices have made PCI incredibly predictable and safe. These advances have allowed operators to intervene in complex, high-risk patients in a way that would not have been conceivable a decade ago. In order to further expand the boundaries of PCI, investigators are testing the utility of hemodynamic support devices as adjunctive therapy for patients at risk of hemodynamic collapse during PCI or in the setting of CS. Nevertheless, currently, the evidence to demonstrate any mortality benefit from the use...
of current hemodynamic support in the setting of CS and high-risk PCI is not clear. However, the limitations of performing randomized trials in this acutely sick group of patients has to be taken into consideration.

Despite the lack of mortality benefits, the devices currently available have been shown to provide hemodynamic support. However, there is a dearth of truly randomized controlled data evaluating the use of hemodynamic support devices and the superiority of one TPLVAD over another for long-term mortality in patients undergoing primary PCI for high-risk MI with tenuous hemodynamics.

The recently completed BCIS and PROTECT II trials have attempted to scientifically study the two most widely available devices – the IABP and Impella 2.5. These trials were successful in identifying high-risk subgroups. One-month mortality was markedly higher than standard drug-eluting stent trials. Thus, an EF of <30% with last patient conduit, unprotected left main or severe triple-vessel disease can be used as a definition of ‘high-risk PCI’. Trends towards improved survival exist for IABP in the BCIS trial. Decreases in major adverse events occurred in patients not undergoing atherectomy in the PROTECT II trial. These trials will hopefully encourage further investigations in these high-risk patients.

At present, IABPs or Impella are not routinely indicated for high-risk PCI. However, because of their ease of use they can provide rapid support in the setting of CS. The data on TandemHeart are limited but the hemodynamic benefits in specific clinical scenarios have to be weighed against the risk of serious vascular complications.

**Future perspective**

As more complex interventions are being performed on sicker patients and technology continues to advance rapidly, the use of TPLVADs is predicted to increase. The indications will continue to expand to support more complex procedures, including structural heart disease and transcatheter valve therapies, as well as in the management of cardiomyopathies and regenerative cell therapy. We envision that in the near future, percutaneous devices with smaller profiles that are simpler to insert and that still provide effective hemodynamic support, will continue to be developed in parallel to the growth in high-risk procedures in the cardiac catheterization laboratory.

Nevertheless, the technological advances demand the need for further well-designed randomized studies that can be applied to this acutely ill population in order to truly define the role that TPLVADs will have in the future.

**Figure 10. Hemodynamic changes with intra-aortic balloon pump support.** (A) Unaugmented arterial pressure waveform. (B) Augmented arterial pressure waveform. (i) One complete cardiac cycle; (ii) unassisted aortic end diastolic pressure; (iii) unassisted systolic pressure; (iv) diastolic augmentation; (v) assisted aortic end diastolic pressure; (vi) reduced systolic pressure. Reproduced with permission from [106].
Executive summary

Indications
- Temporary left ventricular (LV) assist devices are being increasingly used for hemodynamic support in patients with cardiogenic shock and in those undergoing high-risk percutaneous procedures.

Devices available
- The Intra-aortic balloon pump (IABP), Impella® Recover 2.5 and TandemHeart® are the three commonly used and approved percutaneous devices in the USA.

Device selection
- There are specific scenarios and indications in which to select one device over the other and the decision can be: selecting or escalating the support based on the hemodynamic requirements (i.e., IABP→Impella→TandemHeart). This is based on results from small studies and is not currently supported by data from randomized control trials.
- The IABP continues to be the easiest and fastest support, with the fewest complications compared with the rest.
- During high-risk procedures, the device selected will depend on the operators familiarity and comfort level with each device as well as with how much support is desired, depending on the patients intrinsic cardiac reserve and nature of planned intervention.
- In the setting of peripheral vascular disease the device with the lowest vascular profile should be initially selected (IABP→Impella→TandemHeart) in order to avoid vascular complications. Caution should be taken in the cases of Impella and TandemHeart use.

Caution
- Temporary LV assist devices have not been decisively shown to have mortality benefits and can be associated with increased complications, depending on their vascular profile. Nevertheless, they do provide crucial hemodynamic support.
- The use of percutaneous LV assist devices should be performed only in centers with trained staff to be able to manage devices during and after procedure.

Future perspective
- Simple to insert percutaneous devices with smaller vascular profiles, which provide effective hemodynamic support, will continue to be developed with the growth in high-risk procedures in the cardiac catheterization laboratory.

References
Hemodynamic support in high-risk PCI & cardiogenic shock


50 Martinez CA. Hemodynamic Support with Impella 2.5 in High-Risk Interventions for Patients with Aortic Stenosis. Presented at: The 60th Annual Scientific Sessions of the American College of Cardiology, New Orleans, LA, USA, 2–5 April, 2011.

**Websites**

101 Protect II, A Prospective, Multicenter, Randomized Controlled Trial (PROTECT II), www.clinicaltrials.gov/ct2/show/ nct00562016

102 Cardiobridge. www.cardiobridge.com

103 Cath Lab Digest. www.cathlabdigest.com/abiomed-presents-results-from-two-studies-uspella-and-nach-ii

104 Nederlands Trial Register. www.trialregister.nl/trialreg/admin/rctview.asp?tc=1079

